Next, after T cells
NextCure is exploiting myeloid targets to enhance other immunotherapies
PD-1 pioneer Lieping Chen is solving some of the unanswered questions from that breakthrough with his new company, NextCure Inc. The idea is to use myeloid cell factors to boost the effectiveness of other T cell-targeted compounds and extend their uses to non-responders or patients who develop resistance.
The company raised $67 million in series A funding in 2016,